A women-led venture capital is raising a new venture fund and is looking to invest in life science companies that address women’s health between Seed to Series A in Europe, the UK, and Israel, eventually scaling to the U.S as well. Typical check sizes range anywhere between £500k-1M for the first round and will double down up to £2M in Series A. The firm is open to acting as a lead investor for smaller rounds, however they are currently co-investing especially as they start to invest in the U.S.
The firm is open to any life science sector including therapeutics, diagnostics, medical devices, digital health, etc. in the clinical stage as long as the company addresses women’s health. This includes innovations that solely, disproportionately, and/or differently affect women, such as menopause, autoimmune diseases, and heart disease. The firm is open to anywhere from therapeutics and genomics to consumer products. The firm requires to see clinical data and efficacy in the technology. In terms of medical devices, the firm is open to all classes. The only exception that the firm does not invest in is pharmaceuticals.
The firm does not have specific team requirements, however the firm will take a board seat.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Women-Led VC Seeks to Invest in Life Science Companies Addressing Women’s Health, Prioritizing Europe-Based Opportunities
11 MayIntroducing the Panelists at RESI Boston June
4 MayBy Momo Yamamoto, Investor Research Analyst, LSN
Time is flying by, and there is only a month left until RESI Boston! As a refresher, RESI Boston will be a 3-day hybrid conference, taking place on June 5th – 7th. June 5th will be in-person at the Westin Copley Place, featuring Innovator’s Pitch Challenge (IPC) sessions, 7 investor panels, and educational workshops followed by all-day virtual partnering on June 6th – 7th.
Life Science Nation is excited to announce the 20+ panelists who have been selected to speak on our investor panels at RESI Boston. Panel topics include: Big Pharma, Women’s Health, Cell & Gene Therapy, Corporate VC, CNS Diseases, Medtech Strategics, and Digital Health. At this RESI, we will be featuring two new panel topics, Women’s Health and CNS Diseases. Join our seasoned panelists from a wide range of sectors to get the latest insight on trends, emerging topics, advice, and more!
Take a look below for our panelists who will be giving you the latest scoop:
 Elizabeth Bailey Managing Director RH Capital |
 Caleb Bell Venture Partner Corundum Systems Biology |
 Nat Brinn Partner VC23 |
 Frederic Cedrone Vice President, Corporate Innovation Catalent Strategic Ventures |
 Geoff Dacosta Director, Business Development and Licensing Philips Healthcare |
 Neel Desai Business Development & Licensing Biogen |
 Marissa Fayer U.S. Partner Goddess Gaia Ventures |
 Tom Gibbs Director Debiopharm Innovation Fund |
 Lucio Iannone VP of Investments Leaps by Bayer |
 Jotthe Kannappan Associate Intuitive Surgical |
 Arianne Kidder Principal Seae Ventures |
 Joan Koerber-Walker Co-Founder and Managing Member AZBio |
 Adam Kundzewicz Executive Director Boehringer Ingelheim Venture Fund |
 Linda Li Venture Partner Cleveland Clinic Ventures |
 Wasim Malik Co-Founder and Managing Partner Iaso Ventures |
 Amanda Mason Director, Global Head of Inflammation Search & Evaluation, Business Development Amgen |
 John Pennett Angel Investor Mid Atlantic Bio Angels |
 Jane Rho Investor, Venture Fund DaVita Venture Group |
 Ronak Savla Director, Strategic Ventures Catalent Strategic Ventures |
 Yaniv Sneor Founding Member Mid Atlantic Bio Angels |
 Ashim Subedee Director, Catalyst Office Division of Research Innovation and Ventures (DRIVe) |
 David Uffer Vice President, MedTech General Inception |
 Matt Weinberg Partner Max Ventures |
 Sonia Weiss Co-Founder & Managing Partner WPSS.bio |
 Andrew Wong Global Head of Bayer CoLabs Bayer |
 Lu Zhang Managing Partner Fusion Fund |
Have you heard about the Audience Access Pass (AAP) at RESI Boston June?
4 MayBy Antoinette Lowre, Manager of Business Development, LSN
The AAP is a cost-effective way to attend RESI Boston on Monday, June 5th, and network with over 600 early-stage life science startups, investors, and strategic partners. With an AAP, you can join all the live sessions including the Innovator’s Pitch Challenge, investor panels and entrepreneur workshops. This registration option does not include partnering but allows you to take advantage of the educational component of RESI along with the collision factor we see at all our in-person events.
Check out our agenda for Monday, June 5
You can also view the investors who are attending RESI Boston June on our RESI Conference Website which we update frequently so you know who will be a good fit for you to meet in June.
Investor Panel
Innovator’s Pitch Challenge
Entrepreneur Workshop
Want to learn more about RESI and how you can take advantage of the AAP? Reach out to your BD manager and we’d love to answer any questions you may have and learn more about your startup company’s fundraising goals.
|
Life Science Nation Business Development Team
|
|||
|
International
|
East Coast (USA) & China
|
Midwest (USA)
& Canada |
West Coast (USA)
|
 |
 |
|
 |
|
Greg Mannix
Vice President International Business Development Book a Meeting Email Me |
Candice He
VP, Business Development & Global Investment Strategist Book a Meeting Email Me |
Antoinette Lowre
Manager of Business Development Book a Meeting Email Me |
Cameron Hurlburt
Manager of Business Development Book a Meeting Email Me |
Global Tech Hub Gathering in Boston
4 MayBy Erika Wu, Business Development Manager, Global Tech Hubs, LSN
Don’t miss your chance to interact with tech hubs at RESI Boston in June. Tech hubs are a crucial part of the Life Science Nation (LSN) and RESI community as they provide capital, entrepreneurial support, lab space, and economic development for their cohort of aspiring scientist-entrepreneur and fundraising executives. With this immense support from tech hubs, their group of startups, who’ve raised less than $2M USD, can accelerate their entrepreneurship journey by participating in RESI at a discounted rate and taking advantage of LSN services. Ranging from universities, non-profits, incubators, accelerators, and regional and government organizations, they are all looking to connect with investors, strategic partners, and early-stage life science startups in Boston.
Don’t see your organization on this list? Contact us to learn more about the Super Early Bird rate and discounted sponsorship levels for your tech hub and startups.
RESI Boston June 2023 Featured Tech Hubs
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Hot Investor Mandate: Multi-Billion Corporation in Middle East Actively Seeks Investments in Therapeutics, Diagnostics, and Digital Health
4 MayA multibillion corporation headquartered in Saudi Arabia has a venture arm that invests in healthcare. The firm started as an end-to-end logistics and commercialization partner for healthcare products (including pharmaceuticals and medical devices) mainly for global blue chips, with manufacturing facilities in partnership with large corporations. The corporation’s venture arm will be contributing to investments in biotech companies in Series A and later stage companies.
Initial investments will range from $3M-5M in the form of a combination of equity and cash or non-diluted equity if the company has assets that could be leveraged in Saudi Arabia, which includes performing clinical research, manufacturing, and/or commercialization. The firm is predominantly interested in innovative therapeutics, digital health, and personalized diagnostics and with a preference for companies prioritizing US FDA and/or EMA approval. For therapeutics, the firm prefers clinical stage companies. For digital health and diagnostics, the firm prefers companies that have beta tested their product/platforms.
Within therapeutics, the firm is focused on cell and gene therapy in Phase 2 and/or moving into Phase 3, with expectations for accelerated approvals. There are several indications of interest, including rare diseases, oncology, neurodegeneration, immunology, metabolic diseases, therapeutic vaccines, and regenerative therapeutics. Within digital health and diagnostics, the firm is primarily interested in technologies that are enterprise solutions, provider prescribed, personalized medicine or drug discovery engines.
The firm is only interested in companies willing to work with Saudi Arabia toward the goal of bringing biotech innovation to the Gulf and Middle Eastern regions. Relocation is not required, however, a carveout or partnership at least in Saudi Arabia and other Gulf countries is necessary. The firm does not require a board seat but does prefer an observer seat after equity investment.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: VC Seeks Early-Stage Investment Opportunities in Biotech and Digital Health, Especially Those Looking to Expand into Japan
4 MayA venture capital firm headquartered in Japan manages a fund dedicated specifically to life science investments. Though it could largely vary on a deal-by-deal basis, the firm’s initial size of investment is usually around $1M, with a significant portion dedicated to follow-on investments. Geographically, the firm is focused on companies headquartered in Japan and those that are looking to expand into the Japanese market.
The firm is most interested in biotech and digital health technologies. The firm is very interested in emerging therapeutic technologies such as cell and gene therapy, as well as platform technologies. With regards to digital health technologies, the firm is most interested in (i) IT solutions for people in terms of health management, disease prevention, diagnosis, therapy, disease management, and nursing care; (ii) healthcare industry in terms of drug discovery & development, medical information, distribution system by leveraging AI, big data, IoT, VR, etc. The firm is opportunistic in terms of stage, and will seek opportunities that are pre-clinical and beyond.
The firm is actively seeking opportunities in Japan and those that are looking to expand into Japan. The firm will prefer to lead investments in companies headquartered in Japan where they can best leverage their resources and network, but will generally follow larger syndicates for deals outside of Japan.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: USA-Based Venture Firm Invests Up to $10M in Pre-Clinical and Clinical Stage Therapeutics With Novel Approaches
4 MayA venture capital firm headquartered in the US invests in early-stage opportunities to translate key insights in human biology into viable therapeutics. The firm believes that no target is “undruggable” – rather, it is currently “undone”. The firm is open to sharing expertise in developing comprehensive chemical equity strategies and their “whatever it takes” mindset to identify high-quality candidates for clinical proof-of-concept. The firm makes investments ranging from $1-10M in Series A companies focusing in the U.S. and Europe.
The firm focuses mostly on therapeutics in pre-clinical and clinical stages and is drawn to the compelling targets which have emerged from population-wide genetic association studies, where human loss-of-function mutations point to an inhibitor strategy, and gain-of-function mutations provide a gene dose-response. The firm is opportunistic in terms of subsector and indication and is willing to consider companies targeting orphan indications.
The firm looks to act as a lead investor in seed round investments and can participate as either lead or co-investor in series A investments. The firm s looking for companies with skilled and experienced management teams. The firm prefers to support companies that own exclusive IP protection with renowned universities or research institutions. The firm also prefers to work with companies that have a technical expert and experienced in clinical trials.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Subscribe
Life Science Nation
RESI Conference Series
Investor Platform Demo
Company Platform Demo
Next Phase Newsletter 